Church & Dwight Co., Inc. (CHD), the consumer staples maker behind household names such as ARM & HAMMER, OxiClean, Trojan, TheraBreath, Hero, and Batiste, has climbed back toward the top of its 52-week trading range. With the stock recently trading near the $100 mark, investors are increasingly asking whether the shares can push through prior highs and reach the $115 level — the current high end of Wall Street's published price targets.
The $115 price target is not an arbitrary figure. It represents the top of the analyst range for CHD, with firms including Bank of America Securities, Jefferies, and RBC Capital carrying $115 targets on the stock. The broader consensus sits closer to $105, with the average 12-month target near $105–$107 and a median around $108–$110, according to aggregated estimates. For CHD to reach $115, it would first need to clear its 52-week high of $106.04 and then extend beyond the consensus zone — a meaningful but not implausible journey for a steady compounder in the consumer staples sector.
Church & Dwight develops, manufactures, and markets household, personal care, and specialty products, generating roughly $6.2 billion in annual revenue and carrying a market capitalization near $23.6 billion. Its portfolio spans three segments: Consumer Domestic, Consumer International, and Specialty Products, with the United States accounting for the large majority of sales. The stock trades at roughly 31–32 times trailing earnings per share (EPS), a premium to its staples peer group, and pays an annual dividend of about $1.23 per share, or a yield near 1.2%.
Recent financial performance has been resilient but modest. Full-year revenue grew only slightly in fiscal 2025, and management has guided to roughly flat-to-slightly-lower reported sales in 2026 as it laps businesses exited during the prior year. At the same time, the company continues to post volume-driven organic growth and has expanded gross margins, supporting earnings per share that rose in the most recent reported quarter.
Several factors support the idea that CHD could continue climbing toward $115. First, the company is prioritizing high-margin, faster-growing brands such as TheraBreath and Hero, which management and analysts view as a multi-year runway for market share gains. Second, gross margin expansion remains a tailwind, with the company targeting further improvement driven by pricing discipline, productivity, and portfolio mix.
Additionally, Church & Dwight is a consistent capital returner. It has raised its dividend annually for years and operates an ongoing share repurchase program, which reduces share count and supports EPS growth over time. E-commerce now represents roughly a quarter of global revenue, positioning the company to capture direct-to-consumer growth and richer margins. These qualities — defensiveness, steady cash generation, and brand durability — are precisely what investors often pay up for in uncertain economic environments.
The primary obstacle is valuation. At roughly 31–32 times trailing earnings, CHD trades above both its peer average and the broader household products industry, leaving limited room for multiple expansion. If organic growth disappoints or margins stall, the market could compress the stock's premium rather than reward it. Revenue growth has also been subdued, with 2026 guidance reflecting the impact of divested businesses and a cautious consumer backdrop.
Competitive pressure is another risk. Private-label products and aggressive retailer promotion continue to challenge pricing power across consumer packaged goods, and some analysts remain skeptical. Barclays, for example, maintains a Sell rating with a target well below the consensus, reflecting concern that slowing domestic growth and category pressures may outweigh the company's defensive strengths.
Wall Street's consensus rating on CHD is generally Buy, but the dispersion around it is wide. The average price target near $105–$107 implies only modest upside from current levels, while the high estimate of $115 reflects the more optimistic end of the spectrum. Notable bullish targets include Wells Fargo at $110 and Deutsche Bank and Goldman Sachs in the $111–$112 range, while RBC Capital, Bank of America, and Jefferies sit at or near $115. The gap between the $115 high and the $86 low highlights genuine disagreement about whether CHD's premium valuation can be justified.
From a technical standpoint, CHD has been consolidating within a range defined by its 52-week low of $81.33 and its high of $106.04. The area around $95–$96 has acted as near-term support, while $106 represents the first major resistance level. A sustained move above $106 would open the path toward the $110 psychological threshold and, ultimately, the $115 target. Conversely, a failure to hold support could see the stock retrace toward the lower portion of its range, underscoring that reaching $115 is not a foregone conclusion but rather a breakout scenario requiring continued execution.
For traders looking to monitor shifting momentum in stocks and ETFs like CHD, Tickeron's AI Daily Buy/Sell Signals offer an additional layer of insight. The product uses artificial intelligence to continuously scan thousands of securities and generate Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to surface new opportunities, keep watch on existing positions, and identify changing market trends with greater efficiency. Exploring these AI-generated signals can help investors stay informed as price action develops.
Can CHD realistically reach $115? The case is credible but conditional. The company's durable brands, premium positioning, margin momentum, and disciplined capital returns provide a genuine foundation for further gains, and the $115 level is already reflected in the most bullish analyst targets. However, a subdued growth profile, an elevated valuation, and competitive headwinds mean the move is unlikely to be rapid or guaranteed. Reaching $115 would likely require sustained organic growth, continued gross margin expansion, and a decisive breakout above the $106 level that the stock has yet to clear. Investors should monitor quarterly volume trends, margin progress, and the stock's behavior around its 52-week high before drawing conclusions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CHD has been closely correlated with CL. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if CHD jumps, then CL could also see price increases.